Compare EFSI & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFSI | VYGR |
|---|---|---|
| Founded | 1881 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.4M | 194.0M |
| IPO Year | N/A | 2015 |
| Metric | EFSI | VYGR |
|---|---|---|
| Price | $35.00 | $4.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $42.00 | $17.00 |
| AVG Volume (30 Days) | 10.4K | ★ 497.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | $30.82 | N/A |
| Revenue Next Year | $5.36 | $71.77 |
| P/E Ratio | $24.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.70 | $2.65 |
| 52 Week High | $41.12 | $5.55 |
| Indicator | EFSI | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 25.94 | 60.10 |
| Support Level | $34.96 | $3.73 |
| Resistance Level | $36.96 | $4.44 |
| Average True Range (ATR) | 0.98 | 0.24 |
| MACD | -0.39 | 0.08 |
| Stochastic Oscillator | 22.49 | 81.19 |
Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.